Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

264656b8-d45c-4f5c-a431-366c566296fe

5e7f3d5e-6218-5c3d-8ff9-64980fb69ee1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.200
  • PANCREAS_BETA_CELLS+0.200
  • SPERMATOGENESIS+0.200
  • BILE_ACID_METABOLISM+0.100
  • KRAS_SIGNALING_DN+0.100
  • DNA_REPAIR+0.000
  • FATTY_ACID_METABOLISM+0.000
  • HEDGEHOG_SIGNALING+0.000
  • MYC_TARGETS_V1+0.000

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.600
  • ALLOGRAFT_REJECTION-0.500
  • IL6_JAK_STAT3_SIGNALING-0.500
  • INFLAMMATORY_RESPONSE-0.500
  • TGF_BETA_SIGNALING-0.500
  • TNFA_SIGNALING_VIA_NFKB-0.500
  • APICAL_JUNCTION-0.400
  • APOPTOSIS-0.400
  • COMPLEMENT-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-E5-A4U1-01A-11R-A31N-07
bladder-landscape@3
0.943
2TCGA-KU-A66S-01A-21R-A30B-07
head-neck@1
0.932
3SRR5088853
melanoma-umap@29
0.916
4TCGA-DK-AA75-01A-11R-A39I-07
bladder-landscape@3
0.902
5SRR4296068
lung-landscapes@6
cohortA10.895
6TCGA-CF-A47T-01A-11R-A23W-07
bladder-landscape@3
0.893
7R249
bladder-landscape@3
0.888
8SRR1485892
brain-umap@2
GTEX0.886
9MNG887
mng-umap@100
0.886
10TCGA-KQ-A41O-01A-12R-A352-07
bladder-landscape@3
0.880

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 6 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.400Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered